Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Patrick Lamy Sells 8,000 Shares of Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Patrick Lamy sold 8,000 shares of Akero Therapeutics stock in a transaction that occurred on Wednesday, May 7th. The shares were sold at an average price of $42.49, for a total value of $339,920.00. Following the transaction, the vice president now owns 33,492 shares of the company’s stock, valued at approximately $1,423,075.08. This represents a 19.28 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

Patrick Lamy also recently made the following trade(s):

• On Monday, March 3rd, Patrick Lamy sold 1,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $48.09, for a total transaction of $48,090.00.

Akero Therapeutics Price Performance

Shares of Akero Therapeutics stock opened at $39.85 on Friday. The stock has a market capitalization of $3.18 billion, a P/E ratio of -10.63 and a beta of -0.12. The business has a 50 day simple moving average of $41.21 and a two-hundred day simple moving average of $37.43. Akero Therapeutics, Inc. has a 12 month low of $17.86 and a 12 month high of $58.40. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25.

Akero Therapeutics (NASDAQ:AKRO) last posted its quarterly earnings data on Friday, February 28th. The company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.98) by ($0.01). As a group, analysts predict that Akero Therapeutics, Inc. will post -3.99 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently commented on AKRO shares. HC Wainwright raised their price target on shares of Akero Therapeutics from $72.00 to $75.00 and gave the company a “buy” rating in a research report on Monday, March 3rd. Morgan Stanley restated an “overweight” rating on shares of Akero Therapeutics in a research report on Sunday, March 2nd. Citigroup upped their price target on Akero Therapeutics from $65.00 to $80.00 and gave the stock a “buy” rating in a report on Tuesday, January 28th. Bank of America raised Akero Therapeutics from a “neutral” rating to a “buy” rating and raised their price objective for the company from $35.00 to $63.00 in a report on Thursday, January 30th. Finally, UBS Group upped their target price on Akero Therapeutics from $42.00 to $109.00 and gave the stock a “buy” rating in a research note on Friday, January 31st. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Akero Therapeutics currently has an average rating of “Buy” and a consensus price target of $76.29.

Hedge Funds Weigh In On Akero Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of AKRO. GF Fund Management CO. LTD. acquired a new stake in Akero Therapeutics in the 4th quarter valued at about $41,000. PNC Financial Services Group Inc. grew its position in shares of Akero Therapeutics by 30.8% in the first quarter. PNC Financial Services Group Inc. now owns 1,658 shares of the company’s stock valued at $67,000 after purchasing an additional 390 shares in the last quarter. Sterling Capital Management LLC increased its holdings in shares of Akero Therapeutics by 764.3% in the fourth quarter. Sterling Capital Management LLC now owns 1,789 shares of the company’s stock valued at $50,000 after purchasing an additional 1,582 shares during the last quarter. Amalgamated Bank lifted its position in Akero Therapeutics by 19.0% during the first quarter. Amalgamated Bank now owns 2,570 shares of the company’s stock worth $104,000 after buying an additional 410 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in Akero Therapeutics by 14.5% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,664 shares of the company’s stock worth $114,000 after buying an additional 338 shares during the last quarter.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.